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Abstract
Background-Palliation of malignant dysphagia is possible by a variety of methods although all have significant drawbacks. Laser therapy is an effective and safe treatment but has to be repeated at four to five weekly intervals to maintain palliation. A means of augmenting the benefits while reducing the need for repeat treatments would be highly beneficial to these patients. Ains-To prospectively explore the safety and efficacy of intraluminal radiotherapy (brachytherapy) when used to augment laser recanalisation for malignant dysphagia. Patients-Nineteen patients with dysphagia due to advanced adenocarcinoma of the oesophagus or cardia were recruited. Methods-All patients received laser recanalisation until able to swallow a soft diet or better, before the application of a single dose of brachytherapy (10 Gy at 1 cm from the source). Patients were followed up and treated promptly by further endoscopic means in the event of their dysphagia worsening. Results-Six patients (32%) required no further treatment until death at a median of 10 weeks (range 1-20 weeks). Further therapy was required at a median of 11 weeks (range 4-37 weeks) after brachytherapy for those 13 To assist brachytherapy planning, a final endoscopy was performed to place external skin markers (paper clips) at the level of the proximal and distal limits of the tumour using fluoroscopy. A 12 or 14 French Ryles nasogastric tube was then passed into the stomach and the position confirmed with fluoroscopy. The patient was transferred immediately to the Microselectron (Nucleotron UK Ltd, Tattenhall, UK) facility where a limited planning barium swallow was performed, to confirm the tumour limits. Brachytherapy was applied to the length of the tumour plus a 2 cm margin at each end, using a high dose rate Iridium-192 (HDR Ir-192) wire applying 10 Gy at 1 cm from the source. The nasogastric tube was removed immediately after treatment and the patient allowed home as soon as practical.
The majority of laser and brachytherapy treatments were applied on an outpatient basis. Subsequent treatment was only given when swallowing deteriorated to the extent that the patient experienced difficulty with a soft diet, whereupon laser, dilatation or intubation was used according to clinical need. Laser was reapplied to exophytic tumours, dilatation where strictures were predominantly smooth and fibrous due to brachytherapy scarring, with intubation reserved for lesions that had become predominantly extrinsic or where the patient's condition had deteriorated and repeated laser sessions or dilatations were felt unjustified. Intubation, where necessary, was performed using the Celestin tube (Medoc, Tetbury, UK). Efficacy of treatment was judged on the dysphagia scoring, complications, and side effects encountered. Patients were contacted weekly by telephone and interviewed by the author (GMS) or research sister (ST). The interval between brachytherapy and further treatment was deemed the dysphagia free interval.
Informed consent was obtained from all those patients entered in the trial.
Results
Nineteen patients (12 men, seven women; median age 79 years) were recruited into this study. The lesion was deemed incurable on the grounds of local disease stage in nine, verified metastatic disease in two, recurrent disease after previous surgery in one, valvular and ischaemic heart disease in two, and general frailty and old age in the remaining five patients (Table III) . Ten of 19 patients required dilatation, in addition to laser therapy, as part of their initial recanalisation. Grade of dysphagia tnerapy. Snaaea oars represent ayspnagza graae recurrent symptoms requiring further endoscopic therapy, dilatation was required for 10 (77%), laser for nine (69%), and Celestin tube insertion for six (46%), three ofwhom required median of four endoscopies (mean 4 1, subsequent tube adjustments. In those patients 1-9) was required before and including returning for treatment for recurrent dysytherapy. The improvement in dysphagia phagia, further endoscopic treatment was result of this initial recanalisation is required at a mean of nine week intervals, until ated in Figure 1 . Following brachy-death or time of writing with respect to the one py and excluding the survivor, patients survivor.
red a median of two (mean 3.6, range Including the survivor, median survival from further procedures in their lifetime. first treatment was 36 weeks (mean 47 weeks, een patients required further endoscopic range 5-132 weeks) (Fig 3) . The remaining py to maintain palliation, with six patients patient is swallowing a soft diet at 97 weeks. ng no further treatment until death. The Two patients underwent a second brachyan dysphagia free interval following therapy session for recurrent dysphagia at 40 iytherapy, in those requiring subsequent and 49 weeks after the first. They undernent, was 11 weeks (mean 15 weeks, went further laser recanalisation immediately 4-37 weeks). The six (32%) patients followed by brachytherapy applying a further 5 ring no further treatment were able to Gy at 1 cm. Dysphagia relief lasted for another Lte soft diet or better until their death at 11 weeks before both patients required dilathan of 10 weeks (mean 11 weeks, range tation for fibrous stricturing. Radiation weeks) (Fig 2) and mortality of under 1/.12 In addition, one third of patients would expect to swallow a normal diet after laser therapy, with approximately 60% managing a soft diet. Ten per cent would tolerate fluids only and would be classed as laser treatment failures, being offered an alternative treatment modality. It has been established that quality of life is strongly associated with the severity of dysphagia'3 and therefore techniques aimed at relieving dysphagia should lead to an improvement in the quality of life.
When brachytherapy is used without the laser, endoscopic intervention is often necessary to dilate the neoplastic stricture before placement of the source applicator device. It may also be required for the management of treatment failures and recurrent dysphagia, due to fibrous stricturing or tumour regrowth, so the addition of laser therapy is not necessarily a major extra burden for patients. Brachytherapy when applied as a monotherapy has been shown to offer palliation for oesophageal cancer, improving swallowing in 65% of patients treated and lasting for a median duration of 15 weeks.'4 The quality of dysphagia relief was not however quantified. A prospective randomised study comparing brachytherapy with laser treatment revealed similar initial results for both modalities.'5 Initial improvement in dysphagia scores occurred in 91% receiving laser and 83% receiving brachytherapy. This fell to 8 1O% and 75% respectively at two months. Performance scores improved in approximately one third of patients regardless of treatment modality. Sixty six per cent of patients treated with laser and 60% of those treated with brachytherapy were able to tolerate a semisolid diet at death or six month follow up. Retreatment was more common in the laser group, although treatment failures-that is, a failure to relieve dysphagia initially, were identical.
In an early study combining the two, laser recanalisation and brachytherapy together permanently relieved dysphagia in 77% of patients undergoing palliation for either squamous or adenocarcinomas of the oesophagus, cardia and at sites of anastomotic recurrence.'6 Sixteen of 48 patients treated had died at the time of publication with a mean survival of 5.9 months, but no data were given on dysphagia grades. Sander et al,7 in a randomised prospective trial of laser only versus laser plus brachytherapy, found that laser plus brachytherapy doubled the dysphagia free first interval from 30 to 65 days in patients with squamous carcinoma. Those with adenocarcinoma fared less well, and required more frequent endoscopic procedures. Sander suggested, on the basis of this finding and a slightly shorter survival, that supplementary brachytherapy was detrimental in this small subgroup. Recurrent dysphagia developed in all patients living longer than a few weeks or those not having already required intubation for oesophagotracheal fistulae, that is, 72% of patients treated. Our study indicates that brachytherapy following initial laser recanalisation was not detrimental to the patients' well being. Indeed the dysphagia free interval was doubled to 10-1 1 weeks when compared with historical controls receiving laser only, where dysphagia is typically relieved for four to six weeks. Recurrent dysphagia was however seen in all those patients living longer than a few months.
Laser and brachytherapy must be compared with other endoscopic modalities. Intralesion injection of ethanol has been used to recanalise oesophagogastric tumours.`7 This modality has many of the benefits of laser therapy, at a fraction of the cost, but is less precise and still has to be repeated at four weekly intervals to maintain dysphagia relief. The distribution of ethanol when instilled into the tumour is unpredictable and may be quite difficult to control when the tumour is hard and scirrhous in nature. The addition of any form of radiotherapy to augment this form of recanalisation has not been explored.
The placement of silicon rubber tubes to palliate oesophageal cancer predates laser therapy and is still the treatment of first choice in many centres in the UK. Unfortunately, fewer than 10% of patients swallow normally, the majority just tolerating a soft diet. ' 21 The usefulness of expansile metal stents in the palliation of oesophageal carcinoma is not yet clear owing to the continuing evolution of these devices and the limited data currently available. They are also 10 times the cost of conventional tubes. The relative ease of insertion, requiring at most a 12-15 mm dilatation contrasts with the procedure involved with conventional rubber tube placement, where up to an 18 mm dilatation is mandatory. This difference alone probably accounts for the lesser mortality of metal stent insertion when compared with silicon rubber endoprosthesis. Despite this, metal stent insertion may be associated with a morbidity of as high as 17% and mortality of up to 80/,22 although lesser values may become the norm as experience increases. The frequency of recurrent dysphagia is similar for both conventional and metal stents. Knyrim et al23 reported 33% of patients with each type experiencing problems, in the longer term, due to bolus obstruction, tumour overgrowth, tumour ingrowth (metal stents only), prosthesis migration or tracheooesophageal fistula. Grund et al24 found that re-intervention was necessary in 67% of 114 patients treated with metal stents, mainly as a result of tumour ingrowth. An average of 3.5 endoscopic treatments were required per patient during their lifetime including preparatory therapy before stent placement.
These studies suggest that despite initial hopes, expanding metal stents may only offer reasonable palliation when supported by further endoscopic intervention as is the case with laser therapy and rubber tube insertion. Initial studies concerning covered metal stents suggest that while they are free of ingrowth problems, they have the disadvantage of stent migration in up to 1 0% of patients. 25 It is clear that no single treatment modality offers a complete solution to the variety of problems associated with palliating malignant dysphagia. Complementary treatments of confirmed efficacy and patient acceptability are likely to be the way forward. This will demand a degree of expertise and flexibility in terms of the therapeutic options a practitioner has to offer. Further randomised studies are necessary to explore these options while taking into account cost and patient quality of life. A prospective randomised trial is in progress to define more closely the role of brachytherapy when used to augment laser palliation for adenocarcinoma of the oesophagus and cardia. 
